Preview Mode Links will not work in preview mode

Keep up to date on mental health news, free CME, and live events. Subscribe to our podcast and join our email list!

Dec 27, 2023

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer’s disease.

Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click

Learning Objectives: After completing this educational activity, you should be better able to:

    • Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer’s disease
    • Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer’s disease
    • Describe potential future advancements in the diagnosis and treatment of Alzheimer’s disease

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest score of 70% or higher is required to receive CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types: The following are being offered for this activity:

    • Nurse Practitioner: ANCC contact hours
    • Pharmacy: ACPE application-based contact hours
    • Physician: ACCME AMA PRA Category 1 Credits ™
    • Physician Associate: AAPA Category 1 CME credits
    • Psychology: APA CE credits
    • Social Work: ASWB-ACE CE credits
    • Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented.

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma

Dani Cabral, MD

Assistant Clinical Professor, Departments of Neurology and of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ
Dementia Specialist, Banner Sun Health Research Institute, Sun City, AZ

Consultant/Advisor: Eisai, Lilly, Roche/Genentech

Interview Questions Author
Caroline L. O’Brien, MS

Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.

The Planning Committee, Content Editor, and Peer Reviewers have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.

Support: This activity is supported by an unrestricted educational grant from Eisai.

Released: December 27, 2023      CE credit expires: December 27, 2026